|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TCEAL3 |
Gene summary for TCEAL3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TCEAL3 | Gene ID | 85012 |
| Gene name | transcription elongation factor A like 3 | |
| Gene Alias | WEX8 | |
| Cytomap | Xq22.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q969E4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 85012 | TCEAL3 | P75T-E | Human | Esophagus | ESCC | 4.41e-39 | 8.05e-01 | 0.1125 |
| 85012 | TCEAL3 | P76T-E | Human | Esophagus | ESCC | 1.86e-25 | 4.78e-01 | 0.1207 |
| 85012 | TCEAL3 | P79T-E | Human | Esophagus | ESCC | 3.63e-29 | 5.52e-01 | 0.1154 |
| 85012 | TCEAL3 | P80T-E | Human | Esophagus | ESCC | 3.02e-16 | 5.32e-01 | 0.155 |
| 85012 | TCEAL3 | P82T-E | Human | Esophagus | ESCC | 2.09e-06 | 4.00e-01 | 0.1072 |
| 85012 | TCEAL3 | P83T-E | Human | Esophagus | ESCC | 2.48e-31 | 9.36e-01 | 0.1738 |
| 85012 | TCEAL3 | P84T-E | Human | Esophagus | ESCC | 2.16e-03 | 4.42e-01 | 0.0933 |
| 85012 | TCEAL3 | P89T-E | Human | Esophagus | ESCC | 3.94e-15 | 9.15e-01 | 0.1752 |
| 85012 | TCEAL3 | P91T-E | Human | Esophagus | ESCC | 6.22e-14 | 1.43e+00 | 0.1828 |
| 85012 | TCEAL3 | P104T-E | Human | Esophagus | ESCC | 3.33e-07 | 5.95e-01 | 0.0931 |
| 85012 | TCEAL3 | P107T-E | Human | Esophagus | ESCC | 1.32e-08 | 2.09e-01 | 0.171 |
| 85012 | TCEAL3 | P126T-E | Human | Esophagus | ESCC | 4.32e-05 | 4.90e-01 | 0.1125 |
| 85012 | TCEAL3 | P127T-E | Human | Esophagus | ESCC | 8.77e-05 | 1.29e-01 | 0.0826 |
| 85012 | TCEAL3 | P128T-E | Human | Esophagus | ESCC | 4.05e-19 | 6.31e-01 | 0.1241 |
| 85012 | TCEAL3 | P130T-E | Human | Esophagus | ESCC | 4.54e-58 | 1.11e+00 | 0.1676 |
| 85012 | TCEAL3 | C04 | Human | Oral cavity | OSCC | 9.13e-12 | 9.84e-01 | 0.2633 |
| 85012 | TCEAL3 | C21 | Human | Oral cavity | OSCC | 5.57e-21 | 8.45e-01 | 0.2678 |
| 85012 | TCEAL3 | C30 | Human | Oral cavity | OSCC | 8.44e-40 | 1.71e+00 | 0.3055 |
| 85012 | TCEAL3 | C38 | Human | Oral cavity | OSCC | 1.30e-05 | 7.27e-01 | 0.172 |
| 85012 | TCEAL3 | C43 | Human | Oral cavity | OSCC | 1.01e-08 | 2.72e-01 | 0.1704 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TCEAL3 | SNV | Missense_Mutation | c.58N>C | p.Asp20His | p.D20H | Q969E4 | protein_coding | deleterious(0.01) | possibly_damaging(0.657) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| TCEAL3 | SNV | Missense_Mutation | c.451N>C | p.Glu151Gln | p.E151Q | Q969E4 | protein_coding | deleterious(0.03) | possibly_damaging(0.835) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TCEAL3 | SNV | Missense_Mutation | c.244N>A | p.Gly82Ser | p.G82S | Q969E4 | protein_coding | tolerated(0.07) | benign(0.123) | TCGA-E2-A1LS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cyclophosphamide | SD | |
| TCEAL3 | SNV | Missense_Mutation | novel | c.271N>C | p.Glu91Gln | p.E91Q | Q969E4 | protein_coding | tolerated(0.07) | probably_damaging(0.956) | TCGA-UC-A7PG-06 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
| TCEAL3 | SNV | Missense_Mutation | c.4N>A | p.Glu2Lys | p.E2K | Q969E4 | protein_coding | deleterious(0.04) | possibly_damaging(0.737) | TCGA-A5-A0GN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TCEAL3 | SNV | Missense_Mutation | novel | c.52N>T | p.Pro18Ser | p.P18S | Q969E4 | protein_coding | tolerated(0.47) | benign(0.02) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TCEAL3 | SNV | Missense_Mutation | novel | c.289N>A | p.Ala97Thr | p.A97T | Q969E4 | protein_coding | tolerated(0.09) | probably_damaging(0.999) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TCEAL3 | SNV | Missense_Mutation | novel | c.56N>G | p.Glu19Gly | p.E19G | Q969E4 | protein_coding | deleterious(0.01) | benign(0.247) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| TCEAL3 | SNV | Missense_Mutation | novel | c.382N>A | p.Asp128Asn | p.D128N | Q969E4 | protein_coding | tolerated(0.66) | benign(0.086) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| TCEAL3 | SNV | Missense_Mutation | c.514N>T | p.Pro172Ser | p.P172S | Q969E4 | protein_coding | tolerated(0.11) | benign(0.036) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |